Oxidative Stress in Arterial Hypertension
Role of NAD(P)H Oxidase

Guillermo Zalba, Gorka San José, María U. Moreno, María A. Fortuño, Ana Fortuño,
Francisco J. Beaumont, Javier Díez

Abstract—Increased vascular reactive oxygen species production, especially superoxide anion, contributes significantly in the functional and structural alterations present in hypertension. An enhanced superoxide production causes a diminished NO bioavailability by an oxidative reaction that inactivates NO. Exaggerated superoxide levels and a low NO bioavailability lead to endothelial dysfunction and hypertrophy of vascular cells. It has been shown that the enzyme NAD(P)H oxidase plays a major role as the most important source of superoxide anion in vascular cells. Several experimental observations have shown an enhanced superoxide generation as a result of the activation of vascular NAD(P)H oxidase in hypertension. Although this enzyme responds to stimuli such as vasoactive factors, growth factors, and cytokines, some recent data suggest the existence of a genetic background modulating the expression of its different components. New polymorphisms have been identified in the promoter of the p22^phox^ gene, an essential subunit of NAD(P)H oxidase, influencing the activity of this enzyme. Genetic investigations of these polymorphisms will provide novel markers for determination of genetic susceptibility to oxidative stress in hypertension. (Hypertension. 2001;38:1395-1399.)

Key Words: angiotensin II ■ genetics ■ hypertension, arterial ■ stress ■ free radicals

Large amounts of reactive oxygen species (ROS), resulting from oxygen, are produced in vascular cells, including superoxide anion (\(\cdot \text{O}_2^-\)) and hydrogen peroxide (\(\text{H}_2\text{O}_2\)), and act as important intracellular signals. Oxidative stress describes the injury caused to cells by the oxidizing of macromolecules resulting from increased formation of ROS and/or decreased antioxidant reserve. Recent works have reported that all types of vascular cells generate ROS. A growing number of reports have provided a critical role for oxidative stress in the pathogenesis of cardiovascular diseases, including hypertension.\(^1\)

An enhanced production of ROS contributes to the dysregulation of physiological processes, which leads to structural and functional alterations in hypertension.\(^2\) Two characteristic alterations of the vascular wall in hypertension are endothelial dysfunction and vascular smooth muscle cell (VSMC) hypertrophy. An enhanced production of ROS causes a loss of NO bioavailability, which impairs endothelial function, causing (among others) a decreased endothelium-dependent vasodilation.\(^3\) Among these ROS, \(\cdot \text{O}_2^-\) is critically involved in the breakdown of NO.\(^4\) Thus, a diminished availability of NO can be the result of a decreased activity from the NO-production pathway or the result of an increase in the oxidative inactivation of NO by \(\cdot \text{O}_2^-\). Recently, we have shown that endothelial dysfunction is associated with an excess of \(\cdot \text{O}_2^-\) generation rather than a diminished NO production in the aorta of adult spontaneously hypertensive rats (SHR).\(^5\) The presence of unpaired electrons causes \(\cdot \text{O}_2^-\) to be chemically unstable and highly reactive. The reaction of \(\cdot \text{O}_2^-\) with NO leads to the production of peroxynitrite,\(^6\) a potent oxidant believed to be responsible for tissue injury. Peroxynitrite induces the oxidation of proteins, DNA, and lipids in vascular cells.\(^7\) On the other hand, recent findings suggest that increased ROS may stimulate VSMC hypertrophy and hyperplasia.\(^8\) Li et al\(^9\) has shown that \(\cdot \text{O}_2^-\) induces the proliferation of VSMCs, and Zafari et al\(^10\) has proposed a role for \(\cdot \text{O}_2^-\) and \(\text{H}_2\text{O}_2\) in angiotensin II–induced VSMC hypertrophy. ROS are also involved in several signal pathways and in the activation of redox-sensitive transcriptional factors, such as nuclear factor (NF)-kB.\(^11\) It has been shown recently that angiotensin II activates NF-kB in VSMCs.\(^12\) Furthermore, NF-kB has been implicated in the transcription of a number of vascular genes.\(^13\) Finally, NF-kB seems to play a pivotal role in angiotensin II–stimulated ROS generation and inflammatory mechanisms (see review\(^14\)).

Vascular NAD(P)H Oxidase

Enzymatic sources of ROS in the vascular wall playing a functional role in hypertension are NAD(P)H oxidase, NO synthase, xanthine oxidase, and cyclooxygenase. Vascular
Expression of NAD(P)H Oxidase Components in Vascular Cells

<table>
<thead>
<tr>
<th></th>
<th>Endothelial Cells</th>
<th>Fibroblasts</th>
<th>VSMCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>p22phox</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>gp91phox</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>p67phox</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>p47phox</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>rac</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

NAD(P)H oxidase, which is to some extent similar to the previously reported neutrophil NADPH oxidase, is the most important source of \( \cdot O_2^- \) in vascular cells.\(^{15-18}\) The structure and function of this vascular oxidase has been recently reviewed.\(^8\) At present, response to extracellular NAD(P)H is one of the major unanswered questions concerning membrane orientation and function of this oxidase.\(^9\) Vascular NAD(P)H oxidase consists of a cytochrome b558, composed of p22phox and gp91phox subunits and 3 cytosolic components, p47phox, p67phox, and rac. The Table summarizes the expression of these components in vascular cells. Transfection of antisense p22phox demonstrated this subunit of the cytochrome to be essential for functionality of NAD(P)H oxidase.\(^{20}\) Disruption of gp91phox and p47phox subunits lowers vascular \( \cdot O_2^- \) production, without significant alterations in basal blood pressure.\(^{21,22}\) Thus, the existence of compensatory mechanisms regulating blood pressure in this knockout mouse cannot be discarded. Although the gp91phox subunit is absent in VSMCs, the presence of functional isoforms, Nox1 and Nox4, has been reported.\(^{23,24}\) Recently, it has been shown that Nox1 mediates angiotensin II–induced \( \cdot O_2^- \) generation and redox-sensitive signaling pathways in VSMCs.\(^{24}\) Vascular NAD(P)H oxidase is a constitutive enzyme, but it can also be regulated by humoral factors, such as angiotensin II, platelet-derived growth factor, thrombin, tumor growth factor-\( \alpha \), and glucocorticoids,\(^{18,23-28}\) and hemodynamic forces, including laminar and oscillatory shear stress.\(^{29}\)

**NAD(P)H Oxidase in Experimental Hypertension**

**Angiotensin II–Induced Hypertension**

Rajagopalan et al\(^{30}\) demonstrated that chronic infusion of angiotensin II in rats resulted in hypertension in correlation with an increased NAD(P)H oxidase-derived \( \cdot O_2^- \) generation. In the same study, these alterations were corrected by pretreatment of the rats with losartan. Fukui et al\(^{31}\) reported that increased activity of NAD(P)H oxidase in angiotensin II–induced hypertension activated NAD(P)H oxidase by up-regulating the p22phox mRNA levels, a critical component of this oxidase.\(^{20}\) Infusion of recombinant heparin-binding superoxide dismutase (SOD) decreased both blood pressure and p22phox mRNA expression.\(^{31}\)

Recent evidence also suggests the involvement of other subunits in angiotensin II–induced hypertension. Thus, in aortas from angiotensin II–infused mice, there is an increased NAD(P)H-driven \( \cdot O_2^- \) production concomitant with increased protein levels of p67phox and gp91phox subunits that is associated with the elevation of blood pressure.\(^{32}\) Furthermore, these angiotensin II–induced increases were normalized by simultaneous treatment with losartan.

**DOCA-Salt and Renovascular Hypertension**

Somers et al\(^{33}\) showed an enhanced vascular \( \cdot O_2^- \) production associated with impaired endothelium-dependent relaxation in deoxycorticosterone acetate (DOCA)-salt rats, a hypertension model characterized by a low plasma renin activity. Recently, Wu et al\(^{34}\) have reported that the enhanced \( \cdot O_2^- \) production present in the aorta of DOCA-salt hypertensive rats is associated with an increased NADH oxidase activity. It seems that this increased oxidase activity is independent of the rise in blood pressure. It has been suggested that an increased vascular angiotensin II release as a consequence of nephrectomy is the origin of the increased NADH oxidase activity in these rats.

Renovascular hypertension in the 2-kidney, I-clip rat model depends on an increase in circulating angiotensin II levels.\(^{35}\) In this model, NO production is increased,\(^{36}\) and a potential role for \( \cdot O_2^- \) in enhanced NO breakdown has been suggested. Heitzer et al\(^{37}\) showed an increased aortic \( \cdot O_2^- \) generation in this hypertension model associated with an overactivity of NAD(P)H oxidase. Although the mechanism whereby angiotensin II activates NAD(P)H oxidase is still unclear, it might involve a protein kinase C–dependent process.

**Genetic Hypertension**

Several works have recently provided evidence confirming the pathophysiological function of ROS in the SHR. Suzuki et al\(^{38}\) showed an increased \( \cdot O_2^- \) generation in venules and arterioles in these hypertensive rats. Furthermore, Nakazono et al\(^{39}\) demonstrated that administration within the vessel wall of heparin-binding SOD normalized the blood pressure of SHR. Recently, we reported an enhanced NAD(P)H oxidase–driven \( \cdot O_2^- \) production associated with an upregulated p22phox mRNA expression in the aorta of adult SHR with endothelial dysfunction and vascular wall hypertrophy.\(^{40}\)

In the same work, NAD(P)H oxidase–driven \( \cdot O_2^- \) production was not increased in young SHR, which discards a critical role of hypertension in the regulation of oxidase. In this regard, it has been reported that in norepinephrine-induced hypertension, neither \( \cdot O_2^- \) production nor NAD(P)H oxidase is increased.\(^{40}\) Interestingly, we found that both p22phox mRNA expression and NAD(P)H oxidase activity were normalized in adult SHR treated with the angiotensin II type 1 (AT\(_1\)) receptor antagonist irbesartan.\(^{40}\) This suggests a critical role of angiotensin II in the upregulation of this oxidase in the adult SHR. This possibility is further supported by the fact that enhanced expression of both AT\(_1\) receptor and ACE have been reported in vessels of adult SHR.\(^{41}\) As a consequence of an overactivity of the renin-angiotensin system, changes in the degree of activation of vascular cells can regulate p22phox expression. In this regard, we observed that differences in the VSMC phenotype were correlated with changes in the p22phox gene promoter activity.\(^{42}\) Thus, p22phox gene promoter activity was increased in VSMCs isolated from adult SHR compared with those obtained from normotensive Wistar-Kyoto rats (WKY).
On the other hand, upregulation of the oxidase p22phox subunit in the SHR may be consequence of alterations in the sequence of the p22phox gene. In this way we identified 5 polymorphisms in the promoter region of the SHR p22phox gene (Figure 1). Interestingly, the polymorphic SHR promoter possessed functional significance, suggesting that these polymorphisms might be involved in overexpression of the p22phox gene in the vascular wall of the SHR. Taken together, these findings suggest that besides changes in degree of activation of VSMCs associated with the development of hypertension in SHR, the presence of several polymorphisms in the promoter region of the p22phox gene might contribute to the upregulation of p22phox in the vessel wall of SHR. Increased p22phox expression is attenuated by SOD in hypertensive animals, suggesting a role for ·O2− generation and a decreased antioxidant activity. In fact, the levels of ROS scavengers, such as vitamin E, glutathione, and SOD, have been reported to be depressed in hypertensive patients. Furthermore, vitamin C recovers endothelial function by restoring the NO-mediated vasodilation of the endothelium in hypertensive patients.

Berry et al have demonstrated that NAD(P)H oxidase is a source of basal ·O2− production in human internal mammary arteries and saphenous veins. The same authors have reported that angiotensin II increases ·O2− generation in human arteries. This effect is mediated by NAD(P)H oxidase and is completely inhibited by the AT1 receptor antagonist losartan. Higher basal ·O2− concentration in arteries, compared with that in veins, was maintained after endothelial denudation by rubbing, suggesting that VSMCs might be an important source of ·O2− generation in the human arterial wall. Up to now, no studies have been published dealing with vascular NAD(P)H oxidase activity in human hypertension.

Although the relationship between AT1 receptor and NAD(P)H oxidase activity is fascinating, several studies do not show a beneficial effect of ACE inhibitors and AT1 antagonists on endothelial function in patients with essential hypertension. On the other hand, results with these drugs are more convincing in patients with coronary artery disease. Thus, the possibility exists that NAD(P)H oxidase could play a role in patients with a greater cardiovascular risk. Guzik et al have reported a functional effect of the C242T polymorphism on the p22phox gene on NAD(P)H oxidase–driven ·O2− production in the vascular wall of patients with atherosclerosis. Recently, Schachinger et al described an association of the C242T polymorphism with coronary endothelial vasodilator function. Gerdemann et al showed that the association of the A640G polymorphism with the presence and extent of coronary artery disease was stronger in hypertensive than in normotensive subjects. Thus, the role of p22phox polymorphisms via NAD(P)H oxidase–mediated ·O2− production in the development of atherosclerosis in essential hypertension can be hypothesized.

**Conclusion and Perspectives**

Arterial hypertension is associated with an enhanced vascular production of ROS, namely, ·O2−. Overactivity of NAD(P)H oxidase may be critically involved in such an alteration (Figure 2). Thus, this enzyme may play a role in endothelial dysfunction and vascular hypertrophy present in hypertension.
Figure 2. NAD(P)H oxidase activation and functional consequences in arterial hypertension. All indicates angiotensin II; PDGF, platelet-derived growth factor; and TNF-α, tumor necrosis factor-α. Multiple humoral agonists and hemodynamic forces activate NAD(P)H oxidase. Genetic changes may be involved in modulating the expression of the components of NAD(P)H oxidase. An enhanced superoxide anion production driven by NAD(P)H oxidase activation is involved in endothelial dysfunction by decreasing NO bioavailability and is involved in media hypertrophy through the production of H₂O₂.

Besides hemodynamic factors, humoral factors such as angiotensin II may be responsible for altered NAD(P)H oxidase in hypertension (Figure 2), thus allowing for specific pharmacological interventions aimed to reduce oxidative stress in hypertension. The possibility also exists that p22phox gene polymorphisms might regulate oxidase activity in hypertensive patients. Nevertheless, to confirm that these polymorphisms of the p22phox gene are novel markers for hypertensive oxidative stress, investigations in large populations are necessary.

References
6. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci U S A*. 1990;87:1620–1624.


Oxidative Stress in Arterial Hypertension: Role of NAD(P)H Oxidase
Guillermo Zalba, Gorka San José, María U. Moreno, María A. Fortuño, Ana Fortuño, Francisco J. Beaumont and Javier Diez

Hypertension. 2001;38:1395-1399
doi: 10.1161/hy1201.099611

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/38/6/1395

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/